Meningococcal meningitis
MONDO:0018059An acute bacterial disease caused by Neisseria meningitides that presents usually, but not always, with a rash (non blanching petechial or purpuric rash), progressively developing signs of meningitis (fever, vomiting, headache, photophobia, and neck stiffness) and later leading to confusion, delirium and drowsiness. Neck stiffness and photophobia are often absent in infants and young children who may manifest nonspecific signs such as irritability, inconsolable crying, poor feeding, and a bulging fontanel. Meningococcal meningitis may also present as part of early or late onset sepsis in neonates. The disease is potentially fatal. Surviving patients may develop neurological sequelae that include sensorineural hearing loss, seizures, spasticity, attention deficits and intellectual disability.
24 clinical trials for this condition and its sub-types, 18 tagged with Meningococcal meningitis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New meningitis vaccine trial aims to shield babies from deadly infection
Vaccine Recruiting nowThis Phase 3 trial tests a new vaccine designed to protect infants aged 3 to 5 months against four strains of meningococcal bacteria that cause meningitis and sepsis. About 880 healthy babies will receive either the experimental vaccine or a licensed comparator vaccine. Researche…
Phase 3 • Sponsor: Sinovac Biotech Co., Ltd • Aim: Vaccine
Last updated Aug 12, 2026 00:00 UTC
-
New meningitis vaccine trial aims to protect babies
Vaccine Recruiting nowThis Phase 3 trial tests a new vaccine against four types of meningococcal bacteria (A, C, Y, W135) that cause meningitis. About 1,040 healthy infants aged 6 to 11 months will receive either the experimental vaccine or a licensed comparator. Researchers will measure immune respon…
Phase 3 • Sponsor: Sinovac Biotech Co., Ltd • Aim: Vaccine
Last updated Aug 12, 2026 00:00 UTC
-
New meningitis vaccine for toddlers shows promise in major trial
Vaccine Recruiting nowThis study tests a new vaccine to protect young children (12-23 months old) against four types of meningococcal bacteria that can cause meningitis. About 1,040 toddlers will receive either the new vaccine or an existing one to see if the new vaccine is as safe and effective. The …
Phase 3 • Sponsor: Sinovac Biotech Co., Ltd • Aim: Vaccine
Last updated Aug 12, 2026 00:00 UTC
-
One shot to rule them all? new combo vaccine trial for kids begins
Vaccine Recruiting nowThis early-stage trial is testing a new vaccine that combines protection against several serious childhood diseases: diphtheria, tetanus, whooping cough, meningitis, and Hib. The study involves 260 children aged 2 months to 6 years to check the vaccine's safety and immune respons…
Phase 1 • Sponsor: CanSino Biologics Inc. • Aim: Vaccine
Last updated Jun 27, 2026 08:07 UTC
-
Groundbreaking study investigates vaccine response differences across gender and sex
Knowledge-focused Recruiting nowThis study looks at how a person's sex and gender might change their immune system's reaction to the meningitis B vaccine. Researchers will compare immune responses in transgender and cisgender adults aged 18 to 50. The goal is to better understand why men and women often respond…
Phase 4 • Sponsor: University Ghent • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC